Dive Brief:
- AdvaMed said Monday that new Dexcom CEO Jake Leach will lead the diabetes sector for the medtech lobbying group.
- AdvaMed’s diabetes sector represents several diabetes technology companies, including Abbott, Ascensia Diabetes Care, Insulet, Medtronic, Novo Nordisk, Roche Diagnostics and Tandem Diabetes Care.
- Leach became the chief executive of Dexcom in January, after longtime CEO Kevin Sayer stepped down.
Dive Insight:
Leach succeeds Chris Scoggins, Abbott’s executive vice president of diabetes care.
AdvaMed’s diabetes sector advocates for policies to support real-time data, alerts and insights for people with diabetes and prediabetes. The group represents companies whose products may benefit the 40 million people living with diabetes and the 115 million people with prediabetes in the U.S.
AdvaMed CEO Scott Whitaker said in a statement that the sector plays a role in expanding access to diabetes technologies, improving patient outcomes and supporting equitable care for all patients.
Leach has worked at Dexcom for almost 22 years, starting when the company was just 30 employees. He most recently served as chief operating officer before he was promoted to CEO.
